Subscribe to RSS
Please copy the URL and add it into your RSS Feed Reader.
https://www.thieme-connect.de/rss/thieme/en/10.1055-s-00034925.xml
Hamostaseologie 2018; 38(01): 5-6
DOI: 10.1055/s-0038-1637769
DOI: 10.1055/s-0038-1637769
Editorial
Awareness and Attraction or Adhesion and Activation
Further Information
Publication History
received and accepted:
22 January 2018
Publication Date:
26 February 2018 (online)
#
-
References
- 1 Scharf RE. Hamostaseologie – Progress in Haemostasis. Recent achievements and future directions. Hämostaseologie 2016; 36: 157-158.
- 2 Scharf RE. Hot topic: Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. Hämostaseologie 2016; 36: 195-198.
- 3 Tiede A. Thrombotic risks of non-factor replacement therapies in hemophilia. Hämostaseologie 2017; 37: 307-310.
- 4 Shima M, Hanabusa H, Taki M. et al. Factor VIIImimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-2053.
- 5 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818.
- 6 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-828.
- 7 Knobl P. New treatment options for thrombotic thrombocytopenic purpura. Hämostaseologie 2017; 37: 211-215.
- 8 Klamroth R. A new era of treatment for patients with haemophilia A?. Hämostaseologie 2017; 37: 216-218.
- 9 Streif W. Myocardial infarction in a neonate. Lessons for neonatal and internal medicine. Hämostaseologie 2017; 37: 219-222.
- 10 Scharf RE. Pictures tell their own story. Images in Thrombosis and Haemostasis. Hämostaseologie 2017; 37: 181-183.
- 11 Trinchero A, Schotten S, Lammle B, Pitton MB. May-Thurner syndrome: missed diagnosis and missed early treatment?. Hämostaseologie 2017; 37: 184-185.
- 12 Ostergaard S, Hvas AM, Medrud L, Fuglsang J. Ovarian vein thrombosis after delivery. Hämostaseologie 2018; 38: 9-10.
Correspondence to:
Univ.-Prof. Dr. Rüdiger E. Scharf, F.A.H.A.
Email: rscharf@uni-duesseldorf.de
-
References
- 1 Scharf RE. Hamostaseologie – Progress in Haemostasis. Recent achievements and future directions. Hämostaseologie 2016; 36: 157-158.
- 2 Scharf RE. Hot topic: Alloantibodies to therapeutic FVIII and the use of emicizumab in hemophilia A. Hämostaseologie 2016; 36: 195-198.
- 3 Tiede A. Thrombotic risks of non-factor replacement therapies in hemophilia. Hämostaseologie 2017; 37: 307-310.
- 4 Shima M, Hanabusa H, Taki M. et al. Factor VIIImimetic function of humanized bispecific antibody in hemophilia A. N Engl J Med 2016; 374: 2044-2053.
- 5 Oldenburg J, Mahlangu JN, Kim B. et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017; 377: 809-818.
- 6 Pasi KJ, Rangarajan S, Georgiev P. et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017; 377: 819-828.
- 7 Knobl P. New treatment options for thrombotic thrombocytopenic purpura. Hämostaseologie 2017; 37: 211-215.
- 8 Klamroth R. A new era of treatment for patients with haemophilia A?. Hämostaseologie 2017; 37: 216-218.
- 9 Streif W. Myocardial infarction in a neonate. Lessons for neonatal and internal medicine. Hämostaseologie 2017; 37: 219-222.
- 10 Scharf RE. Pictures tell their own story. Images in Thrombosis and Haemostasis. Hämostaseologie 2017; 37: 181-183.
- 11 Trinchero A, Schotten S, Lammle B, Pitton MB. May-Thurner syndrome: missed diagnosis and missed early treatment?. Hämostaseologie 2017; 37: 184-185.
- 12 Ostergaard S, Hvas AM, Medrud L, Fuglsang J. Ovarian vein thrombosis after delivery. Hämostaseologie 2018; 38: 9-10.